Loading...

Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases

Print Friendly, PDF & Email

Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in development NIJMEGEN, the Netherlands – Monday January 27, 2020: Khondrion, a clinical-stage pharmaceutical company discovering […]